Form 4 for HUMA Humacyte, Inc.
Accepted 2023-06-15 00:00:00 ET · period of report 2023-06-13 · accession 0001818382-23-000048 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| I | 2023-06-15 | 2023-06-13 | HUMA | Dougan Brady W | Dir, 10% | S - Sale | $2.60 | -4.88M | 10.49M | -32% | -$12.68M |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2023-06-13 | S | D | 4,875,000 | $2.60 | 10,490,736 | I By Ayabudge LLC | — | — | (F1) The sales were made by Ayabudge LLC, an entity controlled by Brady W. Dougan. The transactions enabled Mr. Dougan to pay down leverage while providing a mechanism for the institutional healthcare investor purchasers to acquire shares of the Issuer at a time that the Issuer was not conducting a financing transaction and was not making any additional shares available for purchase. |